Celyad Oncology S.A.
CYAD
Rank in Stocks
#31669
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Share Price
$0.24706331
Last synced: 2026-10-21
Market Cap
$11.68M
Change (1 day)
-0.81%
Change (1 year)
-47.43%
Country
BE
Trade Celyad Oncology S.A. (CYAD)
Category
Healthcare
Stock price history for Celyad Oncology S.A. (CYAD)
Highest end of day price: $0.59 on 2023-05-01
Lowest end of day price: $53.79 on 2015-06-01
Lowest end of day price: $53.79 on 2015-06-01
Stock price history of Celyad Oncology S.A. from 2015 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2023 | -32.17% |
| 2022 | -78.99% |
| 2021 | -49.41% |
| 2020 | -23.42% |
| 2019 | -46.78% |
| 2018 | -48.41% |
| 2017 | 110.39% |
| 2016 | -62.32% |
| 2015 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.57 | -4.66% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
